Targeted brain cancer drug development

One of the fundamental drawbacks of drug discovery in the CNS area is the underestimation of the role the blood-brain barrier (BBB) plays in the exclusion of drug like molecules. Although technologies such as nanoforumulations and ultrasound have been trialed, there has not been lasting success.

We are developing novel therapeutics, either protein inhibitors or targeted protein degraders, that can cross the blood–brain barrier (BBB) and exhibit tumor tissue specificity. These approaches have the potential to significantly advance CNS drug discovery, particularly for the treatment of brain cancers. Our group specialises in designing such therapeutics, and we are actively seeking collaborations with teams focused on brain cancer biology, animal model development, and preclinical testing of innovative brain cancer therapies.